Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

Clinical Drug Investigation

Volumn 37, Issue 1, 2017, Pages 25-37

  Moćko, Paweł ^a   Kawalec, Paweł ^a   Pilc, Andrzej ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; PLACEBO; VEDOLIZUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ARTHRALGIA; BAYES THEOREM; COUGHING; DRUG SAFETY; DRUG SCREENING; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMMUNOTHERAPY; INFECTION; INFLAMMATORY BOWEL DISEASE; INJECTION SITE REACTION; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAUSEA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; INFLAMMATORY BOWEL DISEASES; NETWORK META-ANALYSIS;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BAYES THEOREM; BIOLOGICAL PRODUCTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; NETWORK META-ANALYSIS;

EID: 84986295312     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-016-0459-y     Document Type: Review

References (50)

1. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1–16.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25. doi:10.1056/NEJMra1102942.
3. Bartnik W. Choroby jelita grubego. In: Gajewski P, editors. Interna Szczeklika—Podręcznik chorób wewnętrznych. Kraków: Medycyna Praktyczna; 2013. p. 942–71 (F).
4. Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–19. doi:10.1016/S0140-6736(12)60150-0.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–29.
6. Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc. 2014;89(12):1621–35. doi:10.1016/j.mayocp.2014.08.019.
7. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–54. doi:10.1053/j.gastro.2014.10.011.
8. Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol. 2015;21(20):6352–60. doi:10.3748/wjg.v21.i20.6352.
9. Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20(43):16014–9. doi:10.3748/wjg.v20.i43.16014.
10. Nanau RM, Cohen LE, Neuman MG. Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci. 2014;17(4):485–531.
11. D’Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007;56(5):725–32.
12. Brignardello-Petersen R, Rochwerg B, Guyatt GH. What is a network meta-analysis and how can we use it to inform clinical practice? Pol Arch Med Wewn. 2014;124(12):659–60.
13. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–7. doi:10.7326/0003-4819-159-2-201307160-00008.
14. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analysis of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84. doi:10.7326/M14-2385.
15. Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):157–73. doi:10.1016/j.jval.2014.01.004.
16. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011.
17. Moćko P, Kawalec P, Pilc A. Analysis of safety profile of biologic agents used in the treatment of inflammatory bowel disease: a systematic review and network meta-analysis. PROSPERO 2015: CRD42015029884 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015029884.
18. van Valkenhoef G, Tervonen T, Zwinkels T, et al. ADDIS: a decision support system for evidence-based medicine. Decis Support Syst. 2013;55:459–75.
19. Gajewski P, Jaeschke R, Brożek J, editors. Podstawy EBM czyli medycyny opartej na danych naukowych dla lekarzy I studentów medycyny. Kraków: Medycyna Praktyczna; 2008.
20. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101(474):447–59.
21. Jonas DE, Wilkins TM, Bangdiwala S, et al. Findings of Bayesian mixed treatment comparison meta-analyses: comparison and exploration using real-world trial data and simulation. Agency for Healthcare Research and Quality (US) 2013. Report No.: 13-EHC039-EF.
22. Ades AE, Welton N, Lu G. Introduction to mixed treatment comparisons. Available at http://www.bristol.ac.uk/social-community-medicine/media/mpes/intro-to-mtc.pdf Accessed 07 Apr 2016.
23. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7(4):434–55.
24. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:6008. doi:10.1136/bmj.f6008.
25. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.
26. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–11. doi:10.1002/ibd.21697.
27. Jiang XL, Cui HF, Gao J, Fan H. Low-dose infliximab for induction and maintenance treatment in chinese patients with moderate to severe active ulcerative colitis. J Clin Gastroenterol. 2015;49(7):582–8. doi:10.1097/MCG.0000000000000319.
28. Hanauer S, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.
29. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.
30. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–50. doi:10.1053/j.gastro.2008.10.051.
31. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65. doi:10.1053/j.gastro.2011.10.032.
32. Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–80. doi:10.1038/ajg.2014.242.
33. Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49(2):283–94. doi:10.1007/s00535-013-0922-y.
34. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
35. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31(12):1296–309. doi:10.1111/j.1365-2036.2010.04304.x.
36. Panaccione R, Colombel JF, Sandborn W, et al. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38(10):1236–47. doi:10.1111/apt.12499.
37. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.
38. Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6:160–73. doi:10.1016/j.crohns.2011.07.013.
39. Watanabe M, Hibi T, Mostafa NM, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn’s disease. J Crohns Colitis. 2014;8(11):1407–16. doi:10.1016/j.crohns.2014.04.012.
40. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109. doi:10.1053/j.gastro.2013.06.010.
41. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. doi:10.1056/NEJMoa1215734.
42. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. doi:10.1056/NEJMoa1215739.
43. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.
44. Sandborn WJ, Lee SD, Randall C, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014;40(8):903–16. doi:10.1111/apt.12930.
45. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.
46. Lichtenstein GR, Thomsen OØ, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8(7):600–9. doi:10.1016/j.cgh.2010.01.014.
47. Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci. 2016;12(5):1097–109. doi:10.5114/aoms.2016.58682.
48. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2011;2:CD008794. doi:10.1002/14651858.CD008794.pub2.
49. Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-a therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(5):447–58. doi:10.1111/apt.12624.
50. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–11. doi:10.7326/M13-2403.